中文

Hong Kong Stocks · Free Data Page

FOSUN PHARMA 02196

FOSUN PHARMA: FY2025 revenue CN¥41.50B (+1.40% YoY); net income CN¥3.37B; 0 alerts, 2 watch items out of 17 risk checks; TTM dividend HK$0.45/sh.
Close PriceHK$17.00Day +0.77%Market CapHK$44.91BP/E11.0xTTMP/B0.77xDividend Yield2.65%TTMROE (FY2025)7.0%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for FOSUN PHARMA?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2016–2025

Financial statements are reported in CNY, while share price and market cap are quoted in HKD.

Key Multi-Year Facts

  • Revenue moved from CN¥14.51B in FY2016 to CN¥41.50B in FY2025 (9-year CAGR +12.4%).
  • Profitable in every fiscal year across 2016–2025.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (CNY B)38.943.841.240.941.5
YoY28.8%12.7%-5.8%-0.8%1.4%
Net Income (CNY B)4.733.742.402.773.37
YoY29.1%-21.0%-35.8%15.5%21.7%
Operating Cash Flow (CNY B)3.944.223.414.485.21
ROE12.4%8.9%5.3%6.0%7.0%
Gross Margin47.9%47.1%47.6%47.8%49.9%
Net Margin12.2%8.5%5.8%6.8%8.1%
Debt-to-Assets48.2%49.5%50.1%49.0%48.5%
Show all 10 fiscal years
Fiscal Year2016201720182019202020212022202320242025
Revenue (CNY B)14.518.424.728.430.238.943.841.240.941.5
YoY—26.6%34.6%14.9%6.2%28.8%12.7%-5.8%-0.8%1.4%
Net Income (CNY B)2.813.122.713.323.664.733.742.402.773.37
YoY—11.4%-13.3%22.7%10.3%29.1%-21.0%-35.8%15.5%21.7%
Operating Cash Flow (CNY B)2.112.582.953.222.583.944.223.414.485.21
ROE12.7%13.2%10.2%11.1%10.7%12.4%8.9%5.3%6.0%7.0%
Gross Margin53.7%58.6%58.1%59.3%54.5%47.9%47.1%47.6%47.8%49.9%
Net Margin19.3%17.0%11.0%11.7%12.1%12.2%8.5%5.8%6.8%8.1%
Debt-to-Assets42.4%52.1%52.4%48.5%45.1%48.2%49.5%50.1%49.0%48.5%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

0Alert 2Watch 15Pass

Items Flagged for Review

  • Watch

    GoodwillFinancial Quality

    CN¥10.76B, 21.4% of equity

    Q3 (2026-09-30) · What is this?

  • Watch

    Short-Term Debt CoverageSolvency

    Cash CN¥13.30B, short-term debt CN¥15.49B (0.86x)

    Q3 (2026-09-30) · What is this?

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

Trailing 12-month dividend: HK$0.450 per share, or 2.65% yield at closing price; last full fiscal year: HK$0.450 (payout ratio 29.7%).

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.